Keros Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Keros Therapeutics, Inc. (KROS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $15.21 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-03
- Keros Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $15.47.
- Keros Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $57.10, a 5.04% increase year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $54.36, a 15.81% increase year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $14.82, a 74.03% decline from fiscal 2024.
- Keros Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $57.07, a 16.33% increase from fiscal 2023.
- Keros Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $49.06, a 12.37% increase from fiscal 2022.
- Keros Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $43.66, a 27.62% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.21 10-Q · filed 2026-08-03 | |||
| 2026-03-31 | $15.47 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $14.82 10-K · filed 2026-03-04 | |||
| 2025-09-30 | $14.82 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $14.82 10-Q · filed 2025-08-06 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $57.07 10-K · filed 2025-02-26 | |||
| 2024-09-30 | $56.17 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $56.93 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $57.10 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $49.06 10-K · filed 2024-02-28 | |||
| 2023-09-30 | $50.27 10-Q · filed 2023-11-06 | |||
| 2023-06-30 | $51.69 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $54.36 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $43.66 10-K · filed 2023-03-03 | |||
| 2022-09-30 | $44.02 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $45.07 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $46.94 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $60.32 10-K · filed 2022-03-09 | |||
| 2021-09-30 | $61.41 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $67.45 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $70.10 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $20.00 10-K · filed 2021-03-25 | |||
| 2020-09-30 | $18.90 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | $18.24 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |